Top Story

Temsirolimus demonstrates short-lived activity in primary CNS lymphoma

May 31, 2016

Temsirolimus monotherapy exhibited clinical activity in patients with relapsed and refractory primary central nervous system lymphoma, although most responses were short lived, according to results of a phase 2 trial.

Researchers also noted temsirolimus increased risk for hematotoxicity and infections that require primary antibiotic prophylaxis.

In the Journals

Triplet chemotherapy may benefit intermediate-, poor-risk germ cell tumors

May 31, 2016
A chemotherapeutic triplet comprised of paclitaxel, ifosfamide and cisplatin exhibited efficacy as first-line treatment for patients with intermediate- or poor-risk germ…

Does chemotherapy cause cancer?

May 31, 2016
Patients with cancer who undergo chemotherapy may be at elevated risk for a new primary cancer several years later.The most common secondary cancers that occur in…
In the Journals

TP53 status may predict response to VEGFR inhibition for advanced sarcoma

May 31, 2016
The TP53 gene mutation may predict improved response to VEGF receptor inhibition among patients with advanced sarcomas, according to a retrospective chart review.Prior…
Meeting News Coverage

Top Takeaways from ASH: Mutations in MDS, AML impact prognosis, spur development of novel agents

May 30, 2016
Findings presented at the ASH Annual Meeting and Exposition contribute to the growing body of literature that demonstrates a correlation between specific gene mutations…
More News Headlines »
CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
At Issue

VIDEO: Wide array of therapeutic options in myeloma a ‘wonderful problem’ for hematologists

May 19, 2016
More »
AACR Annual Meeting

AACR Annual Meeting


The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Current Issues
View the Current Issue
HemOnc Today